MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns

Résumé détaillé

SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into Madrigal Pharmaceuticals, Inc.…

SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). The inquiry focuses on whether Madrigal and senior management misrepresented or concealed material adverse facts concerning the clinical safety data integrity and regulatory compliance of Rezdiffra (resmetirom).

Investors who suffered significant financial losses in Madrigal (NASDAQ: MDGL) securities are encouraged to submit their trading information to Hagens Berman attorneys directly.

The firm's inquiry stems from disclosures made in Madrigal's Quarterly Report filed on Form 10-Q. According to public filings, on October 9, 2026, Dr. Michael Charlton, Madrigal's former Senior Vice President and Head of Clinical Development, filed a whistleblower complaint.

The whistleblower complaint reportedly alleges serious clinical and internal control deficiencies regarding Rezdiffra (resmetirom), including:

Following the revelation of the whistleblower complaint, Madrigal's stock price fell $34.84 per share, or over 8%, to close at $396.32 on heavy trading volume.

"We are investigating the timeline of when Madrigal executives were first alerted to these alleged clinical trial irregularities and whether investors were misled regarding the safety profile and data reliability of Rezdiffra," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Madrigal and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding Madrigal should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

About Hagens BermanHagens Berman is a global…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.